Multicenter Trial of Prednisone in Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00000178
First received: October 29, 1999
Last updated: June 23, 2005
Last verified: February 2005
  Purpose

This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.


Condition Intervention Phase
Alzheimer Disease
Drug: Prednisone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Multicenter Trial of Prednisone in Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by National Institute on Aging (NIA):

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with Alzheimer's disease who are in stable medical condition

Exclusion Criteria:

  • Patients with diabetes or severe osteoporosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000178

Locations
United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35294-0017
United States, California
University of Southern California
Los Angeles, California, United States, 90033
University of California, San Diego
San Diego, California, United States, 92093-0949
United States, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32225
University of Miami
Miami, Florida, United States, 33140
University of South Florida
Tampa, Florida, United States, 33162
United States, Indiana
Indiana University Alzheimer's Center
Indianapolis, Indiana, United States, 46202
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University
St. Louis, Missouri, United States, 63110
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Columbia Presbyterian Medical Center
New York, New York, United States, 11032
New York University Medical Center
New York, New York, United States, 10016
University of Rochester
Rochester, New York, United States, 14620
Burke Medical Research Institute
White Plains, New York, United States, 10605
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212-8646
United States, Texas
University of Texas
Dallas, Texas, United States, 75235-9070
Sponsors and Collaborators
Investigators
Principal Investigator: Leon Thal, MD. University of California, San Diego
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00000178     History of Changes
Other Study ID Numbers: IA0002, 3U01AG10483-08S2
Study First Received: October 29, 1999
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
Alzheimer's disease
Prednisone
Anti-inflammatory agents

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Anti-Inflammatory Agents
Prednisone
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 21, 2014